| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | MANGOCEUTICALS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.08. | Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why | 1 | Benzinga.com | ||
| 04.08. | Mangoceuticals, Inc.: Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination | 182 | GlobeNewswire (Europe) | Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company") today announced it has received an additional 180-calendar-day extension from... ► Artikel lesen | |
| 03.08. | Nuclea Energy To Go Public Through Mangoceuticals Combination With Former Shareholders Owning About 96% | 2 | pulse2.com | ||
| 30.07. | Nuclea Energy Inc: Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor | 845 | Newsfile | Mississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing... ► Artikel lesen | |
| MANGOCEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.07. | Mangoceuticals agrees to merge with nuclear microreactor developer | 6 | Investing.com | ||
| 30.07. | Mangoceuticals kündigt Fusion mit Nukleartechnik-Unternehmen Nuclea an | 4 | Investing.com Deutsch | ||
| 30.07. | Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology | 6.875 | GlobeNewswire (Europe) | Business Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.07. | MANGOCEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.07. | MANGOCEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 02.07. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | MANGOCEUTICALS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.04. | MANGOCEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | MANGOCEUTICALS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 17.03. | Mangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. | 459 | GlobeNewswire (Europe) | Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health... ► Artikel lesen | |
| 06.03. | Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds | 410 | GlobeNewswire (Europe) | Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 23.02. | Mangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study | 236 | GlobeNewswire (Europe) | Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 14.11.25 | Mangoceuticals, Inc.: Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs | 2.320 | GlobeNewswire (Europe) | Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company") is issuing the following clarification regarding its press release issued earlier... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPINEWAY | 0,108 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| NUWELLIS, INC | 0,876 | +0,29 % | Nuwellis, Inc.: Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs | MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced... ► Artikel lesen | |
| LOGICMARK | - | - | EQS-News: Benzinga: From "Text Me When You Get Home" To Always-On Protection: Themes Emerging Across The Evolution Of LogicMark's Aster | EQS-News: Benzinga
/ Key word(s): Healthcare
From "Text Me When You Get Home" To Always-On Protection: Themes Emerging Across The Evolution Of LogicMark's Aster 19.05.2026 / 15:05... ► Artikel lesen | |
| ENVUE MEDICAL | 0,620 | 0,00 % | ENvue Medical, Inc.: ENvue Medical Provides Nasdaq Listing Update | TYLER, Texas, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (Nasdaq: FEED) ("ENvue" or the "Company"), a medical technology company focused on innovative solutions for enteral feeding and... ► Artikel lesen | |
| AGAPE ATP | 2,290 | 0,00 % | Morning Market Movers: Intercont (Cayman), Agape ATP, Astrotech, Snowflake See Big Swings | TOKYO (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 55,85 | -0,03 % | Here's What Lifted BrightSpring Health Services (BTSG) | ||
| ALIGNMENT HEALTHCARE | 8,310 | -0,24 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| HEARTFLOW | 50,37 | +0,08 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,430 | -0,07 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| LIFESTANCE HEALTH GROUP | 12,685 | 0,00 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| GENEDX | 97,78 | -0,05 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| PROGYNY | 26,865 | +0,02 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| BILLIONTOONE | 103,78 | -0,08 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| BETA BIONICS | 22,020 | -0,09 % | Beta Bionics, Inc.: Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its... ► Artikel lesen |